DESTINY-Changing Results for Advanced Breast Cancer
Author:
Affiliation:
1. From the David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.
Publisher
Massachusetts Medical Society
Subject
General Medicine
Link
http://www.nejm.org/doi/pdf/10.1056/NEJMe2206661
Reference9 articles.
1. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
2. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
3. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
4. Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chips
5. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeted drug-loaded peptides induce tumor cell apoptosis and immunomodulation to increase antitumor efficacy;Biomaterials Advances;2024-06
2. Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer;Medical Molecular Morphology;2024-04-15
3. Circ_0011385 increases cisplatin resistance in breast cancer via miR-615-5psuppression;Tropical Journal of Pharmaceutical Research;2024-03-12
4. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis;ESMO Open;2024-02
5. Exosomal miR-361-3p promotes the viability of breast cancer cells by targeting ETV7 and BATF2 to upregulate the PAI-1/ERK pathway;Journal of Translational Medicine;2024-01-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3